BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sachinidis A, Nikolic D, Stoian AP, Papanas N, Tarar O, Rizvi AA, Rizzo M. Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism 2020;111:154343. [DOI: 10.1016/j.metabol.2020.154343] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. The Lancet 2022. [DOI: 10.1016/s0140-6736(22)01655-5] [Reference Citation Analysis]
2 Zhan K, Weng L, Qi L, Wang L, Lin H, Fang X, Jia H, Ma X. Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis. Ann Pharmacother 2022. [DOI: 10.1177/10600280221133577] [Reference Citation Analysis]
3 Polyzos SA, Hill MA, Fuleihan GE, Gnudi L, Kim Y, Larsson SC, Masuzaki H, Matarese G, Sanoudou D, Tena-sempere M, Mantzoros CS. Metabolism, Clinical and Experimental: seventy years young and growing. Metabolism 2022. [DOI: 10.1016/j.metabol.2022.155333] [Reference Citation Analysis]
4 Cigrovski Berkovic M, Rezic T, Bilic-Curcic I, Mrzljak A. Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum? World J Clin Cases 2022; 10(20): 6759-6768 [DOI: 10.12998/wjcc.v10.i20.6759] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sharma A, Virmani T, Sharma A, Chhabra V, Kumar G, Pathak K, Alhalmi A. Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance. Diabetes Metab Syndr Obes 2022;15:1845-64. [PMID: 35733643 DOI: 10.2147/DMSO.S369712] [Reference Citation Analysis]
6 Lok KH, Wareham NJ, Nair RS, How CW, Chuah LH. Revisiting The Concept of Incretin and Enteroendocrine L-cells as Type 2 Diabetes Mellitus Treatment. Pharmacol Res 2022;:106237. [PMID: 35487405 DOI: 10.1016/j.phrs.2022.106237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Elhussein A, Anderson A, Bancks MP, Coday M, Knowler WC, Peters A, Vaughan EM, Maruthur NM, Clark JM, Pilla S; Look AHEAD Research Group. Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the Look AHEAD study. Lancet Reg Health Am 2022;6:100111. [PMID: 35291207 DOI: 10.1016/j.lana.2021.100111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
8 Janić M, Rizzo M, Cosentino F, Pantea Stoian A, Lunder M, Šabović M, Janež A. Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS). Diabetes Ther 2022;13:795-810. [PMID: 35258841 DOI: 10.1007/s13300-022-01226-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Patti AM, Giglio RV, Papanas N, Serban D, Stoian AP, Pafili K, Al Rasadi K, Rajagopalan K, Rizvi AA, Ciaccio M, Rizzo M. Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes. Medicina (Kaunas) 2022;58:109. [PMID: 35056417 DOI: 10.3390/medicina58010109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Weber P, Meluzínová H, Weberová D. New trends in the approach to the treatment of type 2 diabetes - observations and benefits in the outpatient practice of a diabetologist. Klin Farmakol Farm 2022;35:118-123. [DOI: 10.36290/far.2021.027] [Reference Citation Analysis]
11 Hong L, Zha Y, Wang C, Qiao S, An J. Folic Acid Alleviates High Glucose and Fat-Induced Pyroptosis via Inhibition of the Hippo Signal Pathway on H9C2 Cells. Front Mol Biosci 2021;8:698698. [PMID: 34692767 DOI: 10.3389/fmolb.2021.698698] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Lin DS, Lee JK, Hung CS, Chen WJ. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Diabetologia 2021;64:2676-86. [PMID: 34536085 DOI: 10.1007/s00125-021-05529-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
13 Banerjee Y, Pantea Stoian A, Silva-Nunes J, Sonmez A, Rizvi AA, Janez A, Rizzo M. The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf 2021;20:1309-15. [PMID: 34424130 DOI: 10.1080/14740338.2021.1970744] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
14 Patel Chavez C, Cusi K, Kadiyala S. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. J Clin Endocrinol Metab 2021:dgab578. [PMID: 34406410 DOI: 10.1210/clinem/dgab578] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
15 Rizzo M, Nauck MA, Mantzoros CS. Incretin-based therapies in 2021 - Current status and perspectives for the future. Metabolism 2021;122:154843. [PMID: 34333000 DOI: 10.1016/j.metabol.2021.154843] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
16 Lin DS, Lee JK, Chen WJ. Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors. Diabetologia 2021;64:1949-62. [PMID: 34195865 DOI: 10.1007/s00125-021-05497-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
17 Berberich AJ, Hegele RA. Lipid effects of glucagon-like peptide 1 receptor analogs. Curr Opin Lipidol 2021;32:191-9. [PMID: 33900276 DOI: 10.1097/MOL.0000000000000750] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
18 Popovic DS, Rizzo M, Stokic E, Papanas N. New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications? Diabetes Ther 2021;12:1605-11. [PMID: 33945140 DOI: 10.1007/s13300-021-01065-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Pafili K, Papanas N. Considerations for single- versus multiple-drug pharmacotherapy in the management of painful diabetic neuropathy. Expert Opin Pharmacother 2021;:1-14. [PMID: 33819123 DOI: 10.1080/14656566.2021.1909570] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites 2021;11:73. [DOI: 10.3390/metabo11020073] [Reference Citation Analysis]
21 Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites 2021;11:73. [PMID: 33513761 DOI: 10.3390/metabo11020073] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 32.5] [Reference Citation Analysis]
22 Giorgino F, Bhana S, Czupryniak L, Dagdelen S, Galstyan GR, Janež A, Lalić N, Nouri N, Rahelić D, Stoian AP, Raz I. Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa. Diabetes Res Clin Pract 2021;172:108617. [PMID: 33310175 DOI: 10.1016/j.diabres.2020.108617] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
23 Nikolic D, Giglio RV, Rizvi AA, Patti AM, Montalto G, Maranta F, Cianflone D, Stoian AP, Rizzo M. Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect. Diabetes Ther 2021;12:261-74. [PMID: 33210276 DOI: 10.1007/s13300-020-00962-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
24 Giglio RV, Nikolic D, Volti GL, Stoian AP, Banerjee Y, Magan-Fernandez A, Castellino G, Patti AM, Chianetta R, Castracani CC, Montalto G, Rizvi AA, Sesti G, Rizzo M. Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect. Metabolites 2020;10:E391. [PMID: 33008044 DOI: 10.3390/metabo10100391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]